147 completed, 34 unknown, 18 recruiting, 14 terminated. 73 Not applicable, 40 Phase 3, 38 Phase 2, 33 Phase 4, 23 Phase 1.
Follow Vaginosis, Bacterial: new trials by email Literature Review of Vaginosis, Bacterial trials Research Report on Vaginosis, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment metronidazole (MTZ)+ LCFA-01 placebo + LC103 placebo, metronidazole (MTZ)+ LCFA-01 + LC103 placebo, metronidazole (MTZ)+ LC103 + LCFA-01 placebo - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Massachusetts General Hospital | 280 | 2027-02-03 | 2026-10-15 |
| Prevention of Vaginal Cuff Infection After Hysterectomy by Addition of Vaginal Clindamycin Clindamycin Vaginal Gel - Surgical Site Infection, Vaginal Cuff Cellulitis | Enrolling by invitation | Baylor Research Institute | 900 | 2026-12-01 | 2026-10-22 | |
| WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole, Placebo Vaginal Capsule Metronidazole - Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | SPH Sine Pharmaceutical Laboratories Co., Ltd. | 150 | 2026-10-20 | 2026-10-22 |
| AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 1794 | 2026-10-01 | 2026-08-27 |
| Photobiomodulation With Blue LED in Recurrent Bacterial Vaginosis Metronidazole, Blue Light-Emitting Diode (LED) - Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 40 | 2026-09-30 | 2026-09-23 |
| MOTIF@FRESH: Modifying Organisms Transvaginally in Females @ FRESH Vaginal Microbiome Transplantation (VMT), oral metronidazole, Sterile saline solution - Recurrent Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | Douglas Kwon | 75 | 2026-09-01 | 2026-05-18 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment Blue LED Photobiomodulation - Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 150 | 2026-07-30 | 2026-07-13 |
| Efficacy and Safety of a Vaginal Ovule Medical Device for Bacterial Vaginosis and Candidal Vaginitis (ROVUL25). Class IIa vaginal medical device supplied as vaginal ovules, intended as an adjuvant in prevention of vaginal infections and symptoms., Placebo. - Bacterial Vaginosis, Candidal Vaginitis | Not applicable | Not yet recruiting | ROELMI HPC | 80 | 2026-07-09 | 2026-07-14 |
| Large Algorithm Setting and Validation Study Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP - Bacterial Infections, Bacterial Infections and Mycoses | Recruiting | Nanopath, Inc | 1000 | 2026-06-03 | 2026-07-20 | |
| Impact of Clinician-administered Vaginal Live Biotherapeutic Product LC106 - Bacterial Vaginosis | Early Phase 1 | Completed | Caroline Mitchell | 26 | 2026-04-28 | 2026-09-29 |
| The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study Vaginal lactoferrin, Usual care - Bacterial Vaginosis, Candida Vaginal | Not applicable | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 114 | 2026-04-16 | 2026-05-29 |
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota Samples collection (whole blood, urine, vaginal and cervical cells) - Sexual Transmitted Disease, Vaginosis, Bacterial | Recruiting | Centre National de la Recherche Scientifique, France | 300 | 2026-04-07 | 2026-04-09 | |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
| Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial FB 301, Chlorhexidine 0.5%, metronidazole 500 mg - Bacterial Vaginosis (BV) | Phase 2 | Recruiting | Freya Biosciences ApS | 120 | 2026-03-23 | 2026-08-06 |
| Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis Lactobacillus crispatus CRP21, Placebo - Recurrent Bacterial Vaginosis | Not applicable | Recruiting | Liaquat University of Medical & Health Sciences | 132 | 2026-03-23 | 2026-09-02 |
| The Effects of Adjunctive Therapy With Vaginal Tablets Lactobacillus Acidophilus and a Low Dose Estriol (Gynoflor®) to Prolong Pregnancy Time in Preterm Labor, A Randomized Controlled Trial Gynoflor - Threaten Preterm, Prethrem Labour | Not applicable | Not yet recruiting | Queen Savang Vadhana Memorial Hospital, Thailand | 80 | 2026-02-01 | 2026-01-15 |
| An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis pHyph - Bacterial Vaginosis (BV) | Not applicable | Completed | Gedea Biotech AB | 32 | 2026-01-15 | 2026-04-13 |
| A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women GenSci142, Placebo GenSci142 - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 30 | 2025-12-01 | 2025-12-24 |
Showing 20 of 234. Sign in to see all of them.
Vaginitis (27) · Candidiasis, Vulvovaginal (22) · Premature Birth (14) · Trichomonas Vaginitis (11) · Candidiasis (10) · Sexually Transmitted Diseases (10) · Vaginal Diseases (10) · Gonorrhea (7) · Recurrence (7) · Vaginal Discharge (7) · HIV Infections (6) · Trichomonas Infections (6) · Bacterial Infections (5) · Chlamydia Infections (5)
Female Urogenital Diseases and Pregnancy Complications (234) · Genital Diseases (234) · Bacterial Infections and Mycoses (232) · Female Urogenital Diseases (232) · Genital Diseases, Female (231) · Infections (231) · Urogenital Diseases (231) · Bacterial Infections (229) · Vaginal Diseases (224) · Vaginitis (207) · Mycoses (27) · Vulvar Diseases (26) · Vulvitis (25) · Pathological Conditions, Signs and Symptoms (24) · Pathologic Processes (23)
Metronidazole (49) · Clindamycin (11) · Probiotics (6) · Tinidazole (5) · Benchmarking (4) · Lacteol (4) · astodrimer (4) · secnidazole (4) · Anti-Bacterial Agents (3) · Azithromycin (3) · Clotrimazole (3) · NuvaRing (3) · Acetylcysteine (2) · Amphotericin B (2) · Ceftriaxone (2)
National Institute of Allergy and Infectious Diseases (NIAID) (8) · Starpharma Pty Ltd (6) · University of Pittsburgh (5) · Gedea Biotech AB (4) · Skaraborg Hospital (4) · University of Alabama at Birmingham (4) · Vaginal Biome Science (4) · Guangdong Longchuangji Pharmaceutical Co., Ltd. (3) · Hadassah Medical Organization (3) · Peking University Shenzhen Hospital (3) · Peter Humaidan (3) · Symbiomix Therapeutics (3) · University Ghent (3) · University of Washington (3) · Anabio R&D (2)
United States (82) · China (15) · Canada (8) · Israel (8) · Brazil (7) · France (7) · Sweden (7) · Germany (6) · Italy (6) · South Africa (6) · United Kingdom (6) · Kenya (5) · Czechia (4) · Egypt (4) · India (4)
Jeremy Paull, PhD (3) · Caroline Mitchell, MD, MPH (2) · Jane Schwebke, MD (2) · Jeremy Paull, PhD. (2) · Ruifang Wu, M.D. (2) · Sharon L Hillier, PhD (2) · Abigail Norris Turner, PhD (1) · Ahinoam Lev-Sagie (1) · Ahinoam Lev-Sagie, MD (1) · Ahmed R El-Adawy, Professor (1) · Ahmed Y Shahin, MD (1) · Aino Fianu Jonasson, Ass. Prof. (1) · Alan Bocking, MD, FRCSC (1) · Aleksandra M Cichonska, PhD (1) · Amal Mohamed Alanwar, MD (1)
PMID 21854593, PMID 15028938, PMID 16303068, PMID 17128343, PMID 17666604, PMID 18532873, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19616720, PMID 19936044, PMID 20027045, PMID 20370481, PMID 20591191, PMID 20644497, PMID 20801446, PMID 21216000, PMID 21489882, PMID 21789604, PMID 21876923, PMID 21992977, PMID 22059409, PMID 22082722, PMID 22205034, PMID 23746776, PMID 23949590, PMID 24236175, PMID 24431188, PMID 24949544, PMID 24983350, PMID 25127240, PMID 25262105, PMID 25452591, PMID 25935783, PMID 26137971, PMID 26210791, PMID 26611782, PMID 26635090, PMID 26911864, PMID 27093291, PMID 28494795, PMID 28697102, PMID 28807017, PMID 28903767, PMID 29474292, PMID 29637269, PMID 29912913, PMID 30002871, PMID 30184181, PMID 30322724
2023 (1), 2025 (1), KL2RR025754 (1), P30AI027757 (1), R01AI058033 (1), R01AI170564 (1), R01HD077872 (1), R01HD098978 (1), R03TW005820 (1), R21AI111103 (1), U01HD040607 (1), U19AI113173 (1)